



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

September 27, 2023

Corporate Relationship Department  
M/s. BSE Ltd  
Dalal Street, Fort  
Mumbai 400 001

The Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Sir / Madam

Sub:- **Closure of Trading Window**

We wish to inform you that the Trading Window for dealing in the securities of the Company would remain closed for the Directors, Designated Persons, their immediate relatives and all other connected persons covered in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time with effect from **October 1, 2023** to till 48 hours after the declaration of the Financial Results of the Company for the quarter ending September 30, 2023.

Pursuant to SEBI circular SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated July 19, 2023, the Company has designated National Securities Depository Limited (NSDL) as designated Depository Participant of the Company for restricting trading by Designated Persons (“DPS”) by freezing PAN at security level in compliance with the above circular. The Company also updated the Trading Window closure period for the Quarter ending September 30, 2023 along with the relevant details in the NSDL portal.

The date of the Board Meeting for declaration of the financial results of the Company for the quarter ending September 30, 2023 will be intimated in due course of time.

Thanking you

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer